Skip to main content
Erschienen in: Endocrine Pathology 1/2019

04.01.2019 | Pituitary Adenoma

The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas

verfasst von: Rovshan Hasanov, Berna İmge Aydoğan, Saba Kiremitçi, Esra Erden, Sevim Güllü

Erschienen in: Endocrine Pathology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

The fourth edition of the World Health Organization (WHO) classification of pituitary tumors recommended evaluation of tumor proliferation and invasion to identify aggressiveness. We aimed to assess the prognostic roles of the Ki-67 proliferation index, mitotic index, P53 expression, and cavernous sinus invasion in pituitary adenomas (PAs). Among the 601 patients who underwent transnasal/transsphenoidal adenomectomy from 2001 to 2016, 101 patients (16.8%) who had tumors with a high (≥ 3%) Ki-67 index (group A) and a control group consisting of 43 patients with a low (< 3%) Ki 67 index who were matched for age, gender, and tumor type were included. Mitotic index and P53 expressions were evaluated. Patient characteristics, histopathology reports, pre/postoperative magnetic resonance imaging (MRI), and follow-up data were assessed retrospectively. The frequency of macroadenomas and mean tumor size were greater in group A when compared to group B (67.4 vs. 94.1%, p< 0.01 and 25 ± 10.6 vs. 18 ± 11 mm, p< 0.01, respectively). Invasion to cavernous sinus was found in 53 (36.8%) patients and was more frequent in group A (p<0.01). The mean number of surgery was higher in group A than group B (p< 0.05). The mean follow-up period was 46.6 ± 34 months. The postoperative MRIs and follow-up data for at least 24 months were available in 117 patients. Recurrence risk was higher in group A than group B (p = 0.03). Tumors with high Ki-67 proliferation index were grouped as 3–5, 6–10, 11–15, and > 15%. The risk of recurrence was not different between groups of high Ki-67 index. The optimal cutoff point of the Ki-67 proliferation index that predicted recurrence was 2.5% with 84.6% sensitivity and 47.4% specificity. The cavernous sinus invasion on MRI was associated with recurrence (p = 0.03). Tumor size and recurrence risk were not associated with P53 expression. High P53 expression was related with cavernous sinus invasion (p = 0.03). The mitotic index was not associated with recurrence risk and tumor invasion. Recurrence risk was higher in tumors with ≥ 2 histopathological atypia criteria (p = 0.01). High Ki-67 index with a 2.5% cutoff point and cavernous sinus invasion on MRI are reliable markers for predicting recurrence in PAs. Recurrence risk is also higher in tumors with two histopathological aggressiveness criteria. Strict follow-up and more aggressive treatment approaches may be necessary for invasive-proliferative PAs.
Literatur
3.
Zurück zum Zitat Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33 (4):610–617; discussion 617-618PubMed Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33 (4):610–617; discussion 617-618PubMed
4.
Zurück zum Zitat Lloyd RV KK, Young WF, Farrel WE, Asa SL, Truillas J, Kontogeorgos G, Sano T, Scheithauer BW, Horvath E, DeLellis RA, Heitz PU (2004) Pituitary tumors; in WHO Classification of Tumors of the Endocrine Organs: Pathology and Genetics of Endocrine Organs. Lloyd RV KK, Young WF, Farrel WE, Asa SL, Truillas J, Kontogeorgos G, Sano T, Scheithauer BW, Horvath E, DeLellis RA, Heitz PU (2004) Pituitary tumors; in WHO Classification of Tumors of the Endocrine Organs: Pathology and Genetics of Endocrine Organs.
6.
Zurück zum Zitat Chiloiro S, Doglietto F, Trapasso B, Iacovazzo D, Giampietro A, Di Nardo F, de Waure C, Lauriola L, Mangiola A, Anile C, Maira G, De Marinis L, Bianchi A (2015) Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. Neuroendocrinology 101 (2):143–150. doi:https://doi.org/10.1159/000375448 CrossRefPubMed Chiloiro S, Doglietto F, Trapasso B, Iacovazzo D, Giampietro A, Di Nardo F, de Waure C, Lauriola L, Mangiola A, Anile C, Maira G, De Marinis L, Bianchi A (2015) Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. Neuroendocrinology 101 (2):143–150. doi:https://​doi.​org/​10.​1159/​000375448 CrossRefPubMed
7.
Zurück zum Zitat Lloyd RV, Osamura RY, Klöppel G, Rosai J (eds) (2017) WHO classification of tumours of endocrine organs, 4th edn. IARC Press, Lyon. Lloyd RV, Osamura RY, Klöppel G, Rosai J (eds) (2017) WHO classification of tumours of endocrine organs, 4th edn. IARC Press, Lyon.
8.
Zurück zum Zitat Ramirez C, Cheng S, Vargas G, Asa SL, Ezzat S, Gonzalez B, Cabrera L, Guinto G, Mercado M (2012) Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. The Journal of clinical endocrinology and metabolism 97 (5):1745–1751. doi:https://doi.org/10.1210/jc.2011-3163 CrossRefPubMed Ramirez C, Cheng S, Vargas G, Asa SL, Ezzat S, Gonzalez B, Cabrera L, Guinto G, Mercado M (2012) Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. The Journal of clinical endocrinology and metabolism 97 (5):1745–1751. doi:https://​doi.​org/​10.​1210/​jc.​2011-3163 CrossRefPubMed
9.
Zurück zum Zitat Chiloiro S, Bianchi A, Doglietto F, de Waure C, Giampietro A, Fusco A, Iacovazzo D, Tartaglione L, Di Nardo F, Signorelli F, Lauriola L, Anile C, Rindi G, Maira G, Pontecorvi A, De Marinis L (2014) Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review. Pituitary 17 (3):267–276. doi:https://doi.org/10.1007/s11102-013-0500-6 CrossRefPubMed Chiloiro S, Bianchi A, Doglietto F, de Waure C, Giampietro A, Fusco A, Iacovazzo D, Tartaglione L, Di Nardo F, Signorelli F, Lauriola L, Anile C, Rindi G, Maira G, Pontecorvi A, De Marinis L (2014) Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review. Pituitary 17 (3):267–276. doi:https://​doi.​org/​10.​1007/​s11102-013-0500-6 CrossRefPubMed
10.
Zurück zum Zitat Knosp E, Kitz K, Perneczky A (1989) Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 25 (6):927–930CrossRef Knosp E, Kitz K, Perneczky A (1989) Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 25 (6):927–930CrossRef
14.
Zurück zum Zitat Del Basso De Caro M, Solari D, Pagliuca F, Villa A, Guadagno E, Cavallo LM, Colao A, Pettinato G, Cappabianca P (2017) Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. Neurosurgical review 40 (1):105–114. doi:https://doi.org/10.1007/s10143-016-0740-9 CrossRefPubMed Del Basso De Caro M, Solari D, Pagliuca F, Villa A, Guadagno E, Cavallo LM, Colao A, Pettinato G, Cappabianca P (2017) Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. Neurosurgical review 40 (1):105–114. doi:https://​doi.​org/​10.​1007/​s10143-016-0740-9 CrossRefPubMed
15.
Zurück zum Zitat Zakir JC, Casulari LA, Rosa JW, Rosa JW, de Mello PA, de Magalhaes AV, Naves LA (2016) Prognostic Value of Invasion, Markers of Proliferation, and Classification of Giant Pituitary Tumors, in a Georeferred Cohort in Brazil of 50 Patients, with a Long-Term Postoperative Follow-Up. International journal of endocrinology 2016:7964523. doi:https://doi.org/10.1155/2016/7964523 CrossRefPubMedPubMedCentral Zakir JC, Casulari LA, Rosa JW, Rosa JW, de Mello PA, de Magalhaes AV, Naves LA (2016) Prognostic Value of Invasion, Markers of Proliferation, and Classification of Giant Pituitary Tumors, in a Georeferred Cohort in Brazil of 50 Patients, with a Long-Term Postoperative Follow-Up. International journal of endocrinology 2016:7964523. doi:https://​doi.​org/​10.​1155/​2016/​7964523 CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Raverot G, Dantony E, Beauvy J, Vasiljevic A, Mikolasek S, Borson-Chazot F, Jouanneau E, Roy P, Trouillas J (2017) Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification. The Journal of clinical endocrinology and metabolism 102 (9):3368–3374. doi:https://doi.org/10.1210/jc.2017-00773 CrossRefPubMed Raverot G, Dantony E, Beauvy J, Vasiljevic A, Mikolasek S, Borson-Chazot F, Jouanneau E, Roy P, Trouillas J (2017) Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification. The Journal of clinical endocrinology and metabolism 102 (9):3368–3374. doi:https://​doi.​org/​10.​1210/​jc.​2017-00773 CrossRefPubMed
17.
Zurück zum Zitat Mastronardi L, Guiducci A, Puzzilli F (2001) Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. BMC cancer 1:12CrossRef Mastronardi L, Guiducci A, Puzzilli F (2001) Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. BMC cancer 1:12CrossRef
21.
Zurück zum Zitat Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER, Jr. (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38 (1):99–106; discussion 106-107CrossRef Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER, Jr. (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38 (1):99–106; discussion 106-107CrossRef
23.
Zurück zum Zitat Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER, Jr. (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38 (4):765–770; discussion 770-761CrossRef Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER, Jr. (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38 (4):765–770; discussion 770-761CrossRef
24.
Zurück zum Zitat Ozer E, Canda MS, Ulukus C, Guray M, Erbayraktar S (2003) Expression of Bcl-2, Bax and p53 proteins in pituitary adenomas: an immunohistochemical study. Tumori 89 (1):54–59CrossRef Ozer E, Canda MS, Ulukus C, Guray M, Erbayraktar S (2003) Expression of Bcl-2, Bax and p53 proteins in pituitary adenomas: an immunohistochemical study. Tumori 89 (1):54–59CrossRef
25.
Zurück zum Zitat Oliveira MC, Marroni CP, Pizarro CB, Pereira-Lima JF, Barbosa-Coutinho LM, Ferreira NP (2002) Expression of p53 protein in pituitary adenomas. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 35 (5):561–565PubMed Oliveira MC, Marroni CP, Pizarro CB, Pereira-Lima JF, Barbosa-Coutinho LM, Ferreira NP (2002) Expression of p53 protein in pituitary adenomas. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 35 (5):561–565PubMed
Metadaten
Titel
The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas
verfasst von
Rovshan Hasanov
Berna İmge Aydoğan
Saba Kiremitçi
Esra Erden
Sevim Güllü
Publikationsdatum
04.01.2019
Verlag
Springer US
Erschienen in
Endocrine Pathology / Ausgabe 1/2019
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-018-9563-2

Weitere Artikel der Ausgabe 1/2019

Endocrine Pathology 1/2019 Zur Ausgabe

Neu im Fachgebiet Pathologie